Journal Article Summary
The article examines the effectiveness and safety of rivaroxaban, an anticoagulant medication, in patients with symptomatic peripheral artery disease (PAD) who have undergone revascularization procedures. This research is significant because patients with PAD are at high risk for serious cardiovascular events and complications following surgery. The study aims to provide a quantitative benefit-risk evaluation of rivaroxaban compared to aspirin alone, which is commonly used for secondary prevention in these patients.
In the VOYAGER PAD trial, over 6,500 participants were randomly assigned to receive either rivaroxaban (2.5 mg twice daily) plus aspirin or aspirin alone. The study found that rivaroxaban combined with aspirin significantly reduced the risk of major adverse cardiovascular events compared to aspirin alone, with an estimated 120 fewer events per 10,000 patient-years. However, it also resulted in an increase in major bleeding events, particularly nonfatal hemorrhages. The analysis indicated a favorable benefit-risk profile for rivaroxaban, especially in the on-treatment analysis, where the benefits were more pronounced.
Despite the promising results, the study has limitations, including assumptions made in the analysis and the potential variability in health state utility values used for weighting outcomes. Patients should discuss the findings with their healthcare providers to understand how rivaroxaban may fit into their treatment plan, especially considering the risks of bleeding. It is essential for patients to weigh the benefits of reduced cardiovascular events against the potential for increased bleeding when considering this treatment option.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Yuan Zhong, Levitan Bennett, Deng Hsiaowei, Szarek Michael, Bauersachs Rupert M., Berkowitz Scott D., Haskell Lloyd, Barnathan Elliot S., et al.. Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2024. DOI: 10.1161/JAHA.123.032782. PMID: 38563380. PMCID: PMC11262494.
Featured Pill Pals Product
OTC 1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
